Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Jounce Therapeutics
Jounce Therapeutics is a clinical-stage immunotherapy company.
Sector
Subsector
Keywords
Location
total rounds
total raised
Dragonfly Therapeutics
Dragonfly Therapeutics develops cancer treatments using the immune system.
Sector
Subsector
Location
total rounds
Kite Pharma
Kite, a Gilead Company, focuses on cell therapy to cure cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing T cell engagers to treat cancer and other diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 05.08.2014. Their latest investor ARCH Venture Partners. Their latest round Series B
Alaska Permanent Fund
The Alaska Permanent Fund Corporation manages a constitutionally established permanent fund in Alaska.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Bezos Expeditions
Bezos Expeditions is a venture capital firm founded by Jeff Bezos in 2005, primarily investing in Enterprise Software and Internet startups.
Sector
Subsector
Location
count Of Investments
count Of Exists
ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.
Sector
Subsector
Location
count Of Investments
count Of Exists
Bezos Expeditions
Bezos Expeditions is a venture capital firm founded by Jeff Bezos in 2005, primarily investing in Enterprise Software and Internet startups.
Sector
Subsector
Location
count Of Investments
count Of Exists
Venrock
Venrock partners with entrepreneurs to build disruptive, successful companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.
Sector
Subsector
Location
count Of Investments
count Of Exists
Investments3
JW Therapeutics
JW Therapeutics develops and sells cell-based immunotherapies for cancer treatment in China.
Sector
Subsector
Keywords
Location
total rounds
total raised
JW Therapeutics
JW Therapeutics develops and sells cell-based immunotherapies for cancer treatment in China.
Sector
Subsector
Keywords
Location
total rounds
total raised
Editas Medicine
Editas Medicine is a gene-editing company that aims to develop a novel class of human therapeutics to treat genetic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Investors4
Number of lead investors
Number of investors
ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.
Sector
Subsector
Location
count Of Investments
count Of Exists
Robert Nelsen
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation. Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
current job
count Of Investments
Alaska Permanent Fund
The Alaska Permanent Fund Corporation manages a constitutionally established permanent fund in Alaska.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Bezos Expeditions
Bezos Expeditions is a venture capital firm founded by Jeff Bezos in 2005, primarily investing in Enterprise Software and Internet startups.
Sector
Subsector
Location
count Of Investments
count Of Exists
Acquisitions4
RedoxTherapies acquired by Juno Therapeutics
acquirer
date
type
RedoxTherapies
RedoxTherapies re-activates tumor-reactive T cells using adenosine antagonists.
Sector
Subsector
Keywords
Location
AbVitro acquired by Juno Therapeutics
acquirer
date
type
price
AbVitro
AbVitro discovers new therapeutic targets and antibodies for diseases with unmet medical needs.
Sector
Subsector
Location
total rounds
total raised
X BODY acquired by Juno Therapeutics
acquirer
date
type
price
X BODY
X-BODY is a biotechnology company that discovers and develops compounds against targets in oncology and ophthalmology.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders7
Phil Greenberg
Dr. Greenberg graduated from Washington University with a degree in biology. He received his M.D. summa cum laude from the State University of New York, Downstate Medical Center, in 1971. After postdoctoral training in immunology at the University of California at San Diego, he completed his clinical training in medical oncology and joined the faculty of Fred Hutchinson Cancer Research Center and the Division of Oncology at the University of Washington in 1978. He is currently the Head of the Program in Immunology at the Fred Hutchinson Cancer Research Center, and has a joint appointment at the University of Washington as Professor in the Oncology Division of the Department of Medicine and as Professor in the Department of Immunology. Dr. Greenberg’s research has always maintained a focus on both basic immunology and cancer immunobiology as a means to develop translational approaches to treat human malignancies and chronic infections, particularly employing adoptive T cell therapy as a strategy to treat patients with antigen-specific T cells that can selectively target their disease. He has received international recognition as a leader in the field of cancer immunology, as reflected by election to several honorary societies, including the American Society of Clinical Investigation, the American Association of Physicians, the American Association for the Advancement of Science, and the American College of Physicians. He has also been the recipient of two NIH MERIT awards. In 2010 he, along with past and present members of his research group, received the International Society for Immunotherapy of Cancer (SITC) Team Science Award for Career Achievements (2010), and in 2011 he shared, with Steve Rosenberg from the NCI, the Cancer Research Institute’s William B. Coley Award for Distinguished Research in Tumor Immunology for their independent studies to develop and translate adoptive T cell therapy of cancer.
current job
organization founded
Phil Greenberg
Renier Brentjens
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens.
current job
organization founded
Renier Brentjens
Stan Riddell
Stan Riddell is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor of Oncology at the University of Washington School of Medicine. Dr. Riddell is a leader in developing therapies that harness the immune system to fight cancer and infectious diseases. His research led to patented technologies that rapidly expand the number of disease fighting T cells used in adoptive immunotherapy. He also isolated a rare subset of disease-fighting T cells that survive in patients for an extraordinary amount of time. In 2010, Dr. Riddell received the International Society for Biological Therapy of Cancer’s first Team Science Award for major contributions to research and the clinical translation of cancer immunotherapy. Dr. Riddell received his M.D. from the University of Manitoba in Winnipeg. He joined FHCRC Faculty in 1991 after training in medical oncology and immunology. Dr. Riddell was recently elected to the Association of American Physicians, an organization honoring those who have achieved excellence in biomedical science.
current job
organization founded
Stan Riddell
Isabelle Rivière
Isabelle Rivière received her Ph. D. in Cellular and Molecular Biology from the University of Paris in 1993. She initiated her graduate studies in the Interferon Research Group at the Institut Curie, Paris and completed her thesis work in the laboratory of Richard Mulligan,Ph.D at the Whitehead Institute for Biomedical Research, Cambridge, MA. During this time, she developed the MFG/SFG-based gamma-retroviral vectors for in vivo long-term expression of transgenes in hematopoietic cells, which are currently used in multiple clinical trials for the treatment of hereditary blood disorders and cancer. She subsequently worked as a postdoctoral fellow in the laboratory of Dan Littman, MD, Ph.D at New York University, New York, NY. Her studies focused on the regulation of cytokines produce by T helper lymphocytes in vivo, based on a mouse model she developed to track IL-4 secreting T cells using homologous recombination in embryonic stem cells. Dr. Rivière joined the faculty of the Memorial Sloan-Kettering Cancer Center (MSKCC) in 1999. She is currently the Director of the Cell Therapy and Cell Engineering Facility where she investigates novel strategies for cell therapies and immunotherapies to increase or retarget the immune response against tumors and treat hematological disorders. Her laboratory has developed multiple processes for clinical-grade gamma-retroviral and lentiviral vector production as well as hematopoietic and T cell manufacturing. Dr. Rivière serves on the editorial board of Molecular Therapy: Methods and Clinical Development and on multiple committees of the Association of Academic Biologics Manufacturers (AABM), the International Society for Cellular Therapy (ISCT) and the American Society of Gene & Cell Therapy (ASGCT).
current job
organization founded
Isabelle Rivière
Employee Profiles190
Angela Wong
Senior research associate, process development
Jason Bonin
Senior manager, digital marketing - car t